Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

H. Jean Khoury, Jorge E. Cortes, Hagop M. Kantarjian, Carlo Gambacorti-Passerini, Michele Baccarani, Dong Wook Kim, Andrey Zaritskey, Athena Countouriotis, Nadine Besson, Eric Leip, Virginia Kelly, Tim H. Brümmendorf